clinical

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of 

Articles

This year’s hybrid meeting will allow attendees to participate in person or virtually. Either way, this congress will offer a wealth of information to specialists covering all aspects of retinal diseases.

EURETINA 2022: Stepping into the future of ophthalmology

Videos

Nancy Lurker, CEO of EyePoint Pharmaceuticals, shares the 12-month safety data from the DAVIO trial, investigating EYP-1901 for the treatment of wet age-related macular degeneration (AMD) and nonproliferative diabetic retinopathy.

DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden

While the COVID-19 pandemic revealed the potential of utilizing artificial intelligence in screening for diabetic retinopathy, improvements are still needed as a results of the number of images that are ungradable.

Retrospective study compares AI, teleophthalmology diagnosis for diabetic retinopathy

A team of scientists, led by Andrzej Foik, PhD, of the International Center for Translational Eye Research, is working on new therapies that may slow vision loss in patients diagnosed with retinal degeneration.

Fighting pigmentary retinopathy by inhibiting photoreceptor death

Kerrie Brady, CEO of OcuTerra Therapeutics, shares an update on their eye drop-based integrin inhibitor, which is intended to be a novel therapy for diabetic retinopathy.

Diabetic retinopathy eye drop: Phase 1B clinical results show promise

The ASRS "See for a Lifetime; See a Retina Specialist" initiative will spotlight early detection and outline the importance of seeing a retina specialist.

ASRS introduces campaign to increase awareness of retinal disease

The future risk of the development of new-onset vision-threatening diabetic retinopathy, diabetic macular edema, and proliferative diabetic retinopathy can be predicted using the patient’s retinopathy status and hemoglobin A1c value.

New tool emerges for predicting the risk of vision loss from diabetic retinopathy

Metformin, a frequently prescribed drug to treat diabetes, could be a novel therapy for AMD.

Metformin may have a protective effect against AMD

Dr. Diana Do presents data on a novel patient-reported outcome instrument for patients with proliferative diabetic retinopathy with the hope of capturing the burden of the disease and treatment.

Capturing the treatment burden of diabetic retinopathy with novel PRO instrument

According to an e-poster presented by Jagadesh C. Reddy, MD, and Harini Indusekar, BScOptom, at the ASCRS in Washington, D.C., patients who have pre-existing DR are less likely to achieve Snellen 20/40 or better vison after cataract surgery compared with the patients with diabetes but without DR.

Diabetic Retinopathy